Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02033-0/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278989396&_hsenc=p2ANqtz-_DXlyY637YoMBrDB6tCJetmNCw6-jINngS79cQ7v5D6-OH4QlrfTjYir5_xNFjGGmxqaMjqCZog8jKj_b5hcwianVQqQ&utm_content=278989396&utm_source=hs_email